Posted by Michael Wonder on 19 Feb 2020
New hope for lung cancer patients with ground-breaking treatment option to be listed on the PBS
19 February 2020 - Australians with non-small cell and small cell lung cancer or chronic obstructive pulmonary disease will benefit from new and expanded treatment options on the Pharmaceutical Benefits Scheme from 1 March 2020.
The Morrison Government is listing Imfinzi (durvalumab) for the first time for the treatment of non‑small cell lung cancer for patients who have not progressed after chemoradiation.
The Government is expanding the PBS listing of Tecentriq (atezolizumab) to be used in combination with a platinum-based chemotherapy and etoposide for the treatment of small cell lung cancer.
